Opportunities Preloader

Please Wait.....

Report

Global Recombinant Vaccines Market Report and Forecast 2023-2031

Market Report I 2023-04-28 I 147 Pages I EMR Inc.

Global Recombinant Vaccine Market Report and Forecast 2023-2031
Global Recombinant Vaccine Market Outlook
The value of the global recombinant vaccine market was USD 13.32 billion in 2022, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.91% during the forecast period of 2023-2031 to reach a value of USD 36.62 billion by 2031.
Recombinant Vaccine: Introduction
Recombinant vaccines are a type of vaccine that is created by inserting a piece of the pathogen's genetic material, typically DNA or RNA, into a carrier virus or bacteria. This carrier is then used to deliver the genetic material into the body, where it triggers an immune response and the body produces antibodies to fight off the pathogen.
Recombinant vaccines are considered a modern and innovative approach to vaccine development, as they offer several advantages over traditional methods of vaccine production. For example, they can be produced more quickly and with greater precision, and they have a lower risk of contamination or adverse reactions.
Recombinant vaccines have been developed for a variety of diseases, including influenza, hepatitis B, human papillomavirus (HPV), and COVID-19. They are considered a promising area of research for the development of new vaccines, particularly for emerging infectious diseases.
Recombinant Vaccine: Application and Uses
Recombinant vaccines are a type of vaccine that is produced through genetic engineering techniques. These vaccines are made using recombinant DNA technology to produce specific antigens, which are then used to stimulate the immune system and create an immune response against a specific pathogen. Recombinant vaccines have a variety of applications, including:
- Prevention of infectious diseases: Recombinant vaccines are used to prevent infectious diseases such as hepatitis B, human papillomavirus (HPV), and influenza.
- Treatment of cancer: Recombinant vaccines are being developed to treat cancer by stimulating the immune system to target and destroy cancer cells.
- Veterinary medicine: Recombinant vaccines are used to prevent diseases in animals, including livestock and pets.
- Biodefense: Recombinant vaccines are being developed to protect against potential bioterrorism threats, such as anthrax and smallpox.
- Allergies: Recombinant vaccines are used to treat allergies by desensitizing the immune system to specific allergens.
Overall, the use of recombinant vaccines is growing due to their safety, effectiveness, and versatility.
Global Recombinant Vaccine Market Segmentations
Market breakup by Type
- Live Attenuated
- Subunit

Market breakup by Disease Indication
- Hepatitis B
- Rotavirus
- Herpes Zoster
- Meningococcal B
- Others

Market by Distribution Channel
- Hospitals
- Vaccination Centres

Market by End User
- Paediatrics
- Adults
- Veterinary

Market Breakup by Region

North America
- United States of America
- Canada

Europe
- United Kingdom
- Germany
- France
- Italy
- Others

Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

Latin America
- Brazil
- Argentina
- Mexico
- Others

Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Global Recombinant Vaccine Market Scenario
The global recombinant vaccine market is expected to witness significant growth in the coming years owing to the increasing prevalence of infectious diseases, technological advancements in vaccine development, and the growing demand for vaccines across the world are some of the key factors driving the growth of the market.
Subunit vaccines are expected to hold the largest share of the market due to their lower risk of side effects and better immunogenicity.
Based on technology, the market is divided into conjugate vaccines, inactivated and subunit vaccines, and live attenuated vaccines. Conjugate vaccines are expected to hold the largest share of the market due to their high effectiveness against various diseases
Based on application, the market is divided into infectious diseases, cancer, and others. Infectious diseases are expected to hold the largest share of the market due to the high prevalence of infectious diseases across the world.
Based on end user, the market is divided into pediatrics, adults, and others. Pediatrics are expected to hold the largest share of the market due to the high demand for vaccines in children.
North America is expected to dominate the market due to the high adoption of advanced vaccines and the presence of major players in the region. However, the Asia Pacific region is expected to witness the highest growth in the coming years due to the increasing prevalence of infectious diseases and the growing demand for vaccines in the region.
Key Players in the Global Recombinant Vaccine Market
The report gives an in-depth analysis of the key players involved in the global recombinant vaccine market. The companies included in the market are as follows:
- GSK plc
- Pfizer Inc.
- Sanofi
- Walvax Biotechnology Co., Ltd. (Walvax)
- Dynavax Technologies Corporation
- Merck & Co., Inc.
- Novartis AG
- GC Biopharma
- Bayer AG
- Bharat Biotech
- Sartorius AG
- Serum Institute of India Pvt. Ltd.
- Bio Farma





1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Recombinant Vaccine Market Overview
3.1 Global Recombinant Vaccine Market Historical Value (2016-2022)
3.2 Global Recombinant Vaccine Market Forecast Value (2023-2031)
4 Global Recombinant Vaccine Market Landscape
4.1 Global Recombinant Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Recombinant Vaccine Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Disease Indication
4.2.3 Analysis by Distribution Channel
4.2.4 Analysis by End User
5 Global Recombinant Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Recombinant Vaccine Market Segmentation
6.1 Global Recombinant Vaccine Market by Type
6.1.1 Market Overview
6.1.2 Live Attenuated
6.1.3 Subunit
6.2 Global Recombinant Vaccine Market by Disease Indication
6.2.1 Market Overview
6.2.2 Hepatitis B
6.2.3 Rotavirus
6.2.4 Herpes Zoster
6.2.5 Meningococcal B
6.2.6 Others
6.3 Global Recombinant Vaccine Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Vaccination Centres
6.4 Global Recombinant Vaccine Market by End User
6.4.1 Market Overview
6.4.2 Paediatrics
6.4.3 Adults
6.4.4 Veterinary
6.5 Global Recombinant Vaccine Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Recombinant Vaccine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Recombinant Vaccine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Recombinant Vaccine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Recombinant Vaccine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Recombinant Vaccine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 GSK plc
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sanofi
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Walvax Biotechnology Co., Ltd. (Walvax)
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Dynavax Technologies Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Merck & Co., Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 GC Biopharma
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Bayer AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Bharat Biotech
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Sartorius AG
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bio Farma
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Recombinant Vaccine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE